#Biosimilars are biologic medical products that are highly similar to already approved brand-name biologics, with no significant differences in safety, purity, or effectiveness. They are developed after the original product's patent expires, offering more affordable treatment options. Biosimilars play a key role in expanding patient access to life-saving biologic therapies. Read More: https://wemarketresearch.com/reports/biosimilar-market/5 #Biologics #AffordableMedicine #HealthcareInnovation #PatientAccess #Pharma #Biotech #BiosimilarMedicines

Biologics Market Growth, Opportunities, Industry Applications, Analysis and Forecast by 2031 https://www.datalibraryresearch.com/reports/biologics-market-2516

Fill Finish Biopharmaceuticals market Share, Growth Analysis by 2035 Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill and finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities. The financial opportunity within the biologics fill finish services market has been analysed across the following segments:  Type of Packaging Container  Ampoules  Cartridges  Syringes  Vials  Type of Biologic  Antibodies  Cell Therapies  Gene Therapies  Oligonucleotides  Proteins / Peptides  Vaccines  Others  Therapeutic Area  Oncological Disorders  Autoimmune Disorders  Infectious Diseases  Cardiovascular Disorders  Other Disorders  Scale of Operation  Preclinical / Clinical  Commercial  Company Size  Large  Mid-sized  Small  Key Geographical Regions  North America  Europe  Asia-Pacific  Middle East and North Africa  Latin America The “Biologics Fill / Finish Services Market (3rd Edition), 2022 – 2035” report features the following companies, which we identified to be key players in this domain:  AbbVie Contract Manufacturing  Asymchem  BioReliance  Boehringer Ingelheim BioXcellence  Catalent Biologics  Charles River Laboratories  Fareva  Fresenius Kabi  Glaxo SmithKline  Hetero Drugs  Intas Pharmaceuticals  Lonza  Patheon  Pierre Fabre  Recipharm  Samsun Biologics  Syngene  Takara Bio  Wacker Biotech  WuXi AppTec  WuXi Biologics Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Biologics Fill / Finish Service Providers: Market Landscape 5. Company Competitiveness Analysis 6. Biologics Fill / Finish Service Providers in North America 7. Biologics Fill / Finish Service Providers in Europe 8. Biologics Fill / Finish Service Providers in Asia-Pacific 9. Recent Partnerships 10. Recent Expansions 11. Capacity Analysis 12. Demand Analysis 13. Key Performance Indicators for Biologic Manufacturing and Fill / Finish 14. Regional Capability Assessment 15. Biologics Fill Finish Market Sizing and Opportunity Analysis 16. Future Growth Opportunities 17. Case Study: Robotic Systems in Fill / Finish Operations 18. Case Study: Ready-To-Use Packaging Components for Aseptic Fill / Finish 19. Concluding Remarks 20. Executive Insights 21. Appendix 1: Tabulated Data 22. Appendix 2: List of Companies and Organizations To view more details on this report, click on the link https://www.rootsanalysis.com/reports/view_document/biologics-fill-finish-services-market/256.html News article women's digital health market Learn from experts: do you know about these emerging industry trends? Bioavailability Enhancement Technologies TIL Therapies: A New Paradigm in Cancer Treatment Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #FillFinishManufacturing #FillFinishManufacturingMarket #BiologicsFillFinish #MarketResearch #MarketInsights

Intracellular Drug Delivery market Growth Analysis and Forecast by 2035 The growing demand for novel drugs that can acts as potential treatments for previously untreatable intracellular targets has resulted in an adjacent and urgent need for efficient delivery systems that facilitate intracellular transport of therapeutics across the cytosol The financial opportunity within non-viral drug delivery systems market has been analyzed across the following segments:  Type of Molecule  Small Molecule  Biologic  Type of Biologic  Antibodies  DNA  RNA  Proteins / Peptides  Type of Intracellular Drug Delivery Technologies  Cell Penetrating Peptides  Extracellular Vesicles  Oligonucleotides  Nanoparticles  Polymers  Target Therapeutic Area  Infectious Diseases  Oncological Disorders  Genetic Disorders  Neurological Disorders  Hepatic Disorders  Cardiovascular Disorders  Other Disorders  Type Of Payment Model  Upfront Payments  Milestone Payments  Key Geographical Regions  North America  Europe  Asia  Latin America  Middle East and North Africa (MENA)  Rest of the world The Non-Viral Drug Delivery Systems Market: Focus on Intracellular Technologies and Biologics (2nd Edition), 2022-2035, report features the following companies, which we identified to be key players in this domain:  Alnylam Pharmaceuticals  AstraZeneca  Biond Biologics  Code Biotherapeutics  Eli Lilly  Merck  Novartis  Roche Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Key Insights 6. Company Competitiveness Analysis 7. Company Profiles 8. Patent Analysis 9. Partnerships and Collaborations 10. Opportunity Assessment Framework 11. Market Forecast 12. Conclusion 13. Executive insights 14. Appendix I: Tabulated data 15. Appendix II: List of Companies and Organizations To view more details on this report, click on the link https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html News article AI-based Digital Pathology Market Learn from experts: do you know about these emerging industry trends? Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic? Exploring How Artificial Intelligence Is Transforming Digital Pathology About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #nonviraldrugdeliverysystemmarket #Intracellularbiologics #intracellulardelivery #MarketResearch #MarketInsights

Opportunities in RNA Therapeutics market 2023 – Industry Growth by 2035 RNA therapies have emerged as a promising treatment modality, with the potential to target and alter genes, modulate protein functions and broaden the range of druggable targets, thereby paving way for new avenues in disease diagnosis and treatment. With rise in government initiatives for early commercialization of pipeline therapies and active involvement of RNA therapeutics investors, we anticipate a variety of novel RNA based therapeutics to be developed, presenting lucrative opportunities for both short- and long-term investors. The financial opportunity within the RNA therapeutics market has been analyzed across the following segments:  Type of Therapy  mRNA Vaccines and Therapeutics  RNAi Therapeutics  RNA Aptamers  Therapeutic Area  Infectious Diseases  Genetic Disorders  Haematological Disorders  Metabolic Disorders  Ocular Disorders  Oncological Disorders  Renal Disorders  Route of Administration  Intradermal  Intramuscular  Intravenous  Intravitreal  Ophthalmic  Subcutaneous  Key Geographies  North America  Europe  Asia-Pacific  Middle East and North Africa  Latin America The Investor Series: Opportunities in the RNA Therapeutics Market (mRNA Therapeutics and Vaccines, RNAi Therapeutics, and RNA Aptamers), detailed profiles of key public ventures engaged in the development of RNA therapeutics; each profile features a brief overview of the company, along with information on its management team, insights from its balance sheet (if available), as well as details related to its product portfolio, recent developments and key financials (including company investment highlights, company fundamental and company technical analysis).  Arcturus Therapeutics  Ascletis Pharma  Avidity Biosciences  BioNtech  CanSino Biologics  Gritstone bio  IVERIC bio  Moderna  Phio Pharmaceuticals  Vir Biotechnology Table of Contents Excel Deliverables 1. Innovators and Products Dataset 2. RNA therapeutics Funding and Investment Analysis 3. Company Valuation Analysis 4. Fundamental Financial Analysis 5. Technical Financial Analysis 6. Business Risk Analysis 7. Market Forecast and Opportunity Analysis 8. Return on Investment PowerPoint Deliverable 1. Context 2. Project Approach 3. Project Objective 4. Executive Summary Section I: Introduction to RNA Therapeutics and Innovators Landscape 5. The RNA Therapeutics Market 6. RNA Therapeutics: Innovators Landscape 7. RNA Therapeutics: Products Landscape and Company Health Indexing 8. Value Proposition Analysis 9. Company Competitiveness Analysis Section II: Analysis of RNA therapeutics Investment and Company Valuation 10. Funding and Investment Analysis 11. Company Valuation Analysis Section III: Financial Analysis and Assessment of Business Risks 12. Financial Analysis of Public Ventures 13. Company Profiles of Public Ventures 14. Business Risk Assessment Section IV: Market Forecast and Opportunity Analysis 15. Market Forecast and Opportunity Analysis Section V: Analysis of Returns on Investment and Key Acquisition Targets 16. Analysis of Return on Investment 17. Key Acquisition Targets 18. Conclusion 19. Appendices To view more details on this report, click on the link https://www.rootsanalysis.com/reports/opportunities-in-rna-therapeutics-market.html Learn from experts: do you know about these emerging industry trends? T-cell Immunotherapies: The Future of Modern Cancer Treatments Monkeypox: Disease Overview, Transmission and Diagnosis Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #RNATherapeuticsFumding #RNATherapeuticsInvestment #RNATherapeuticsInvestors #Marketresearch #MarketInsights

Filtration market Analysis and Trends by 2023-2035 The biopharmaceutical filtration market has been growing rapidly in recent years, driven by the increasing demand for biologics, as well as advances in filtration technologies. It is a critical step in the manufacturing process of biopharmaceutical products, and its applications are essential in ensuring the safety, quality, and efficacy of the final product. The financial opportunity within the biopharmaceutical market has been analyzed across the following segments:  Type of Filtration System  Depth Filtration System  Tangential Flow Filtration Systems  Membrane Filtration System  Other Filtration Systems  Type of Filter (based on use)  Disposable / Single-use Filters  Reusable / Multi-use Filters  Type of Assembly  Capsules  Cartridges  Others  Type of Drug Product  Antibodies  Vaccines  Recombinant Proteins  Cell Therapies  Gene Therapies  Oligonucleotides  Others  Company Size  Small / Mid-sized  Large  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The “Global Filtration Market (Focus on Biologics Manufacturing), 2023 – 2035” report features the following companies, which we identified to be key players in this domain:  Asahi Kasei  Cobetter Filtration  Corning  Merck  Pall  Parker Hannifin  Sartorius  Thermo Fisher Scientific Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Biopharmaceutical Filtration: Market Landscape 5. Company Competitiveness Analysis 6. Suppliers Headquartered in North America: Company Profiles 7. Suppliers Headquartered in Europe and Asia-Pacific: Company Profiles 8. Recent Developments 9. Global Events Analysis 10. Biopharmaceutical Filtration: Market Forecast and Opportunity Analysis 11. Conclusion 12. Executive Insights 13. Appendix 1: Tabulated Data 14. Appendix 2: List of Companies and Organizations To view more details on this report, click on the link https://www.rootsanalysis.com/reports/global-filtration-market.html Learn from experts: do you know about these emerging industry trends? TCR Therapies: An Emerging Therapeutic Modality Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #membranefiltrationmarket #membranefiltrationsystem #pharmaceuticalfiltrationmarket #MarketResearch #MarketInsights

3D Bioprinting: Intellectual Property Landscape market 2022 – Industry Growth by 2035 The new market report titled ‘3D Bioprinting: Intellectual Property Landscape,’ published by Roots Analysis features an extensive study of some of the key historical and contemporary intellectual property (IP) documents (featuring granted patents, patent applications and other documents), describing the various types of 3D bioprinting. The insights generated in this report have been presented across two deliverables, namely a MS Excel workbook and a MS PowerPoint deck, summarizing the ongoing trend in this domain. To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/3d-bioprinting-intellectual-property-landscape.html Main Chapters in the 3D Bioprinting Intellectual Property Landscape Report  Overall Intellectual Property Landscape An analytical perspective of the various patents and affiliated IP documents that have been published related to 3D bioprinting, since 2000. An in-depth analysis of published IP documents, representing unique patent families across various global jurisdictions, featuring insightful inferences related to both historical and recent R&D trends within this domain.  Popular / Relevant Prior Art Search Expressions An examination of IP literature, shortlisting key words and phrases used to describe 3D bioprinting. The analysis also includes details on the historical use of the aforementioned terms across different IP filings, key affiliated terms and other related trends.  Patent Valuation Analysis A competitive benchmarking and valuation analysis of the key members of unique patent families captured in the report, taking into consideration important parameters of the patent application.  Patentability and Freedom to Operate A systematic and Roots Proprietary approach to identify relevant areas of innovation by analyzing published IP documents, by defining the uniqueness of patented / patent pending innovations, in order to assess the scope of patentability in this domain, and pinpoint jurisdictions wherein new and / or modified claims may be filed without infringing on existing IP.  Analysis of Patent Applications and Granted 3D Bioprinting Patents A detailed summary of the various patent applications and granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis classified the intellectual capital in terms of type of innovation and the innovation related to 3D bioprinting, thereby offering the means to identify active arenas of research and assess innovation-specific IP filing trends.  Pockets of Innovation and White Spaces An insightful analysis of the various CPC codes used in published IP literature and their affiliated families, offering the means to identify historical and existing pockets of innovation, the analysis also features a discussion on prevalent white spaces.  Claim Analysis One of the objectives of the report was to analyze and summarize key inferences from the independent claims mentioned in granted, active patents in the dataset. Using a systematic segregation approach, we have analyzed trends associated with the preamble, type of patent, type of claim and other key elements of a claim. Key Companies Profiled  Hewlett-Packard (HP)  CELLINK  Organovo  Revotek  ROKIT Healthcare  T&R Biofab  Aspect Biosystems  Prellis Biologics  Advanced Solutions Life Sciences  Cyfuse To understand the complete structure of the report, get its PDF sample copy https://www.rootsanalysis.com/reports/3d-bioprinting-intellectual-property-landscape/request-sample.html You may also be interested in the following titles: Cell Therapy Manufacturing Market Global TCR Therapy Market You may also like to learn what our experts are sharing in Roots educational series: Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market? CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #Threedimensionalbioprinting #3dbioprintingpatents #3Dbioprinting #3Dbioprintinginvestments #3DbioprintingIPlandscape

non-viral drug delivery system market 2022 – Industry Growth by 2035 Roots Analysis has announced the addition of “Non-Viral Drug Delivery Systems Market: Focus on Intracellular Technologies and Biologics (2nd Edition), 2022-2035” report to its list of offerings. Key Market Insights  Presently, over 90 non-viral drug delivery systems developers are engaged in the healthcare market, located across the globe  Currently, more than 95 non-viral drug delivery systems are offered by several players in the healthcare domain  The partnership activity for non-viral drug delivery systems in the healthcare domain has grown at a CAGR of over 40%, in the past three years, 2018-2021  The projected future opportunity for companies engaged in this field is expected to be well distributed across type of molecule, type of biologic delivered, type of technology, target therapeutic area, type of payment model and key geographical regions. Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Market Segmentations 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Need for Targeted Drug Delivery 3.3. Advanced Approaches for Delivery of Drug Payloads 3.3.1. Nanoparticle Delivery Systems 3.3.1.1. Liposomes 3.3.1.2. Nanoparticles / Microparticles 3.3.1.3. PEGylation 3.3.1.4. Cell Penetrating Peptides (CPPs) 3.3.2. Other Drug Delivery Technologies 3.4. Future Perspectives 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Intracellular Drug Delivery: List of Technologies 4.2.1. Analysis by Type of Molecule Delivered 4.2.2. Analysis by Type of Biologic Delivered 4.2.3. Analysis by Type of Interaction 4.2.4. Analysis by Therapeutic Portfolio 4.3. Intracellular Drug Delivery: List of Technology Developers 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Company Size 4.3.3. Analysis by Type of Company 4.3.4. Analysis by Location of Headquarters (By Region) 5. KEY INSIGHTS 5.1. Chapter Overview 5.2. Analysis by Type of Technology 5.3. Analysis by Company Size and Type of Molecule Delivered 5.4. Analysis by Location of Headquarters (Region-wise) and Type of Service Provider 5.5. Analysis by Company Size and Location of Headquarters 6. COMPANY COMPETITIVENESS ANALYSIS 6.1. Chapter Overview 6.2. Assumptions / Key Parameters 6.3. Methodology 6.4. Company Competitiveness Analysis: Benchmarking of Portfolio Strength 6.5. Company Competitiveness Analysis: Benchmarking of Partnership Strength 6.5.1. Company Competitiveness Analysis: Very Small Companies 6.5.2. Company Competitiveness Analysis: Small Companies 6.5.3. Company Competitiveness Analysis: Mid-Sized Companies 6.5.4. Company Competitiveness Analysis: Large and Very Large Companies 7. COMPANY PROFILES 7.1. Arcturus Therapeutics 7.2. Bio-Path 7.3. CureVac 7.4. Entos Pharmaceuticals 7.5. eTheRNA immunotherapies 7.6. Matinas BioPharma 7.7. MDimune 7.8. PCI Biotech 8. PATENT ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Intracellular Drug Delivery Technologies: Patent Analysis 8.3.1. Analysis by Type of Patent 8.3.2. Analysis by Publication Year 8.3.3. Analysis by Application Year 8.3.4. Analysis by Cumulative Number of Granted Patents 8.3.5. Analysis by Cumulative Number of Patent Applications 8.3.6. Analysis by Issuing Authority 8.3.7. Analysis by Type of Player 8.3.8. Leading Players: Analysis by Number of Patents 8.3.9. Leading Inventors: Analysis by Number of Patents 8.3.10. Analysis by Top Sections 8.3.11. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis 8.4. Intracellular Drug Delivery Technologies: Patent Valuation Analysis 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations 9.3.1. Cumulative Analysis of Partnerships by Year, 2015-2022 9.3.2. Analysis by Type of Partnership 9.3.3. Analysis by Year and Type of Partnership, 2015-2022 9.3.4. Analysis by Purpose of Partnership 9.3.5. Analysis by Type of Molecule Delivered 9.3.6. Analysis by Type of Biologic Delivered 9.3.7. Analysis by Target Therapeutic Area 9.3.8 Analysis by Year of Partnership and Type of Payment Model Employed, 2015-2022 9.3.9. Analysis by Year of Partnership and Type of Company, 2015-2022 9.3.10. Analysis by Purpose of Partnership and Type of Company 9.3.11. Most Active Players: Analysis by Number of Partnerships 9.3.12. Most Popular Technologies: Analysis by Number of Partnerships 9.3.13. Analysis by Region 9.3.14. Local and International Agreements 9.3.15. Intracontinental and Intercontinental Agreements 10. OPPORTUNITY ASSESSMENT FRAMEWORK: KALBACH INNOVATION MODEL, COMPETITVE ASSESSMENT FRAMEWORK AND BCG MATRIX 10.1. Chapter Overview 10.2. Kalbach Innovation Model 10.2.1. Key Assumptions and Methodology 10.2.2. Analysis by Trends in Research Activity 10.2.3. Analysis by Trends in Investment Activity 10.2.4. Analysis by Trends in Partnership Activity 10.2.5. Analysis by Number of Technologies 10.2.6. Analysis by Trends in Deal Amount 10.2.7. Analysis by Number of Google Hits 10.2.8. Qualitative and Quantitative Assessment based on Secondary and Primary Research 10.2.9. Kalbach Innovation Model: Output Analysis 10.3. Competitive Assessment Framework 10.3.1. Key Assumptions and Methodology 10.3.2. Competitive Assessment Framework: Output Analysis 10.4. BCG Matrix 10.4.1. Key Assumptions and Methodology 10.4.2. BCG Matrix: Output Analysis 11. MARKET FORECAST AND OPPORTUNITY ANALYSIS 11.1. Chapter Overview 11.2. Key Assumptions 11.3. Forecast Methodology 11.4. Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035 11.5. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035 11.5.1 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035 11.5.2 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035 11.6. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035 11.6.1 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035 11.6.2 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035 11.7. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035 11.7.1 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035 11.7.2 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035 11.7.3 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035 11.7.4 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035 11.8. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Technology, 2022 and 2035 11.8.1. Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035 11.8.2 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035 11.8.3 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035 11.8.4 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035 11.8.5 Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035 11.9. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Areas, 2022 and 2035 11.9.1 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035 11.9.2 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035 11.9.3 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035 11.9.4 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035 11.9.5 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035 11.9.6 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035 11.9.7 Non-Viral Intracellular Drug Delivery Technologies Market for Other Diseases, 2022-2035 11.10. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035 11.10.1. Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035 11.10.2. Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035 11.10.3. Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035 11.10.4. Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022- 2035 11.10.5. Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035 11.10.6. Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035 12. CONCLUDING REMARKS 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Biond Biologics 13.2.1. Interview Transcript: Tehila BenMoshe, Chief Executive Officer and Itay Friedman, Vice President Clinical Development 13.3. Carmine Therapeutics 13.3.1. Interview Transcript: Don Haut, Chief Executive Officer 13.4. Eyevensys 13.4.1. Interview Transcript: Thierry Bordet, Chief Scientific Officer 13.5. Generation Bio 13.5.1. Interview Transcript: Maren Killackey, Senior Director, Investor Relations and Communications 13.6. PCI Biotech 13.6.1. Interview Transcript: Anders Høgset, Research Director / Chief Scientific Officer 13.7. SRI International 13.7.1. Interview Transcript: Melissa Wagner, Strategic Business Executive, Biosciences Division 14. APPENDIX 1: TABULATED DATA 15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html You may also be interested in the following titles: Global Antibiotics Market Pharmaceutical Polymers / Medical Polymers Market You may also like to learn what our experts are sharing in Roots educational series: Advancements in Automation of Processes: Key Value Driver for Escalated Interest in Cell Therapies Manufacturing Domain CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #nonviraldrugdeliverysystemmarket #nonviraldrugdeliverysystemmarketSize #genedeliverysystems #intracellulardelivery #intracellulardrugdelivery

Exosome Therapeutics market Growth Analysis and Forecast by 2035 Roots Analysis has done a detailed study on Exosome Therapeutics Market, 2022-2040, covering key aspects of the industry and identifying future growth opportunities Key Market Insights  Close to 60 players, worldwide, have taken initiatives to develop exosome therapeutics; the market is characterized by the presence of start-ups and small companies  The current pipeline features more than 120 exosome therapeutics that are being evaluated across different phases of development; most of these are designed for intravenous administration  3,000+ patients have been recruited / enrolled in clinical trials evaluating exosome related therapies and biomarkers across different geographies  More than 530 grants have been awarded for the ongoing R&D efforts for exosome therapeutics; University of California has been awarded the maximum grant amount of USD 21 million  A variety of investors, having realized the benefits and future opportunities in this field, have invested more than USD 570 million across more than 30 instances, since 2017  The rising interest of stakeholders in exosome therapeutics is also reflected by the increasing number of partnerships established by various industry and non-industry players  Stakeholders have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities existing in this domain  At present, more than 30 start-ups are driving innovation in this domain; a variety of R&D initiatives have been undertaken by these players over the last few years for the development of exosome therapeutics  Lack of efficacy, COVID-19 pandemic, limited patient enrollment, and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players  With the rising demand for therapeutic advances in drug safety, the market of exosome therapeutics is expected to grow at an annualized rate of 41% between 2029-2040  The projected market opportunity is likely to be well distributed across different routes of administration, types of formulations and key geographical regions Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Overview of Exosomes 3.1.1. Types of Extracellular Vesicles 3.1.1. Potential Sources of Exosomes 3.2. Exosome Biogenesis 3.2.1. Exosome Formation and Development Process 3.2.2. Secretion of Exosomes 3.3. Applications of Exosomes 3.4. Mechanism of Exosome Therapy 3.4.1. Exosome Drug Therapy 3.4.2. Exosome RNAi Therapy 3.4.3. Exosome Immunotherapy 3.5. Advantages of Exosome Therapies 3.6. Risks and Future Perspectives Associated with Exosome Therapeutics 4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE 4.1. Analysis Methodology and Key Parameters 4.2. Exosome Therapeutics Market Landscape 4.2.1. Analysis by Phase of Development 4.2.2. Analysis by Technology Platform 4.2.3. Analysis by Type of Payload 4.2.4. Analysis by Derived Source 4.2.5. Analysis by Target Disease Indication(s) 4.2.6. Analysis by Therapeutic Area 4.2.7. Analysis by Phase of Development and Therapeutic Area 4.2.8. Analysis by Therapeutic Area and Route of Administration 4.2.9. Analysis by Route of Administration 4.2.10 Analysis by Area of Application 4.2.11. Analysis by Type of Therapy 4.2.12. Analysis by Dosing Frequency 4.2.13. Analysis by Type of Therapy (By Method of Composition) 4.2.14. Analysis by Line of Treatment 4.3. Exosome Therapeutics Developers 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Company Size 4.3.3. Analysis by Location of Headquarters 4.3.4. Most Active Players: Analysis by Number of Therapeutics 5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES 5.1. Coya Therapeutics 5.1.1. Company Overview 5.1.2. Product Portfolio 5.1.3. Recent Developments and Future Outlook 5.2. Codiak BioSciences 5.3.1. Company Overview 5.3.2. Product Portfolio 5.3.3. Clinical Trial Information 5.3.4. Recent Developments and Future Outlook 5.4. Evox Therapeutics 5.4.1. Company Overview 5.4.2. Product Portfolio 5.4.3. Recent Developments and Future Outlook 5.5. Curexsys 5.5.1. Company Overview 5.5.2. Product Portfolio 5.5.3. Recent Developments and Future Outlook 5.6. EV Therapeutics 5.6.1. Company Overview 5.6.2. Product Portfolio 5.6.3. Recent Developments and Future Outlook 5.7. SHIFTBIO 5.7.1. Company Overview 5.7.2. Product Portfolio 5.7.3. Recent Developments and Future Outlook 6. EXOSOME THERAPEUTICS: DRUG PROFILES 6.1. AEGLE Therapeutics 6.1.1. Company Overview 6.1.2. AGLE-102: Product Portfolio 6.1.2.1. AGLE-102: Clinical Trial Information 6.1.3. Recent Developments and Future Outlook 6.2. AVEM Healthcare 6.2.1. Company Overview 6.2.2. Ardoxso: Product Portfolio 6.2.2.1. Ardoxso: Clinical Trial Information 6.2.3. Recent Developments and Future Outlook 6.3. Cellular Biomedicine Group 6.3.1. Company Overview 6.3.2. Financial Information 6.3.3. haMPC-Exos: Product Portfolio 6.3.3.1. haMPC-Exos: Clinical Trial Information 6.3.4. hMSC-Exos: Product Portfolio 6.3.4.1. hMSC-Exos: Clinical Trial Information 6.3.5. Undisclosed Drug 1: Product Portfolio 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information 6.3.6. Recent Developments and Future Outlook 6.4. OBCTCD24 6.4.1. Company Overview 6.4.2. CovenD24: Product Portfolio 6.4.2.1. CovenD24: Clinical Trial Information 6.4.3. Recent Developments and Future Outlook 6.5. ReNeuron 6.5.1. Company Overview 6.5.2. Financial Information 6.5.3. Undisclosed Drug 1: Product Portfolio 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information 6.5.4. Recent Developments and Future Outlook 6.6. Stem Cell Medicine 6.6.1. Company Overview 6.6.2. Undisclosed Drug 1: Product Portfolio 6.6.3. Recent Developments and Future Outlook 7. CLINICAL TRIAL ANALYSIS 7.1. Analysis Methodology and Key Parameters 7.2. Exosome Therapeutics: List of Clinical Trials 7.2.1. Analysis by Trial Status 7.2.2. Analysis by Trial Registration Year 7.2.3. Analysis by Sponsor / Collaborator 7.2.4. Analysis by Trial Registration Year and Type of Study 7.2.5. Analysis by Trial Registration Year and Trial Status 7.2.6. Analysis by Annual Number of Patients Enrolled 7.2.7. Analysis by Study Design 7.2.8. Analysis by Age Category 7.2.9. Analysis by Phase of Development and Trial Status 7.2.10. Analysis by Phase of Development and Patients Enrolled 7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials 7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials 7.2.13. Analysis by Trial Location 7.2.14. Analysis by Trial Status and Geography 7.2.15. Analysis by Trial Status, Patients Enrolled and Geography 8. ACADEMIC GRANT ANALYSIS 8.1. Analysis Methodology and Key Parameters 8.2. Exosome Therapeutics: List of Academic Grants 8.3. Analysis by Year of Grants Awarded 8.4. Analysis by Amount Awarded per Year 8.5. Analysis by Type of Funding Institute Center 8.6. Analysis by Support Period 8.7. Analysis by Purpose of Grant 8.8. Word Cloud Analysis: Emerging Focus Area 8.9. Analysis by Grant Activity Code 8.10. Analysis by Location of Recipient Organizations 8.11. Popular Recipient Organizations: Analysis by Number of Grants 8.12. Popular Recipient Organizations: Analysis by Amount Awarded 8.13. Analysis by Type of Recipient Organization 8.14. Analysis by Study Section 8.15. Analysis by Type of Grant Application 8.16. Analysis by Funding Institute Center and Support Year 9. GLOBAL EVENT ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. List of Global Events Related to Exosomes 9.3.1. Analysis by Year of Event 9.3.2. Analysis by Event Platform 9.3.3. Analysis by Type of Event 9.3.4. Analysis by Region 9.3.5. Most Active Organizers: Analysis by Number of Events 9.3.6. Most Active Speakers: Analysis by Number of Events 9.3.7. Most Active Industry Participants: Analysis by Number of Events 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events 9.3.9. Analysis by Designation of Participant 9.3.10. Analysis by Affiliated Department of Participant 9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area 10. PARTNERSHIPS AND COLLABORATIONS 10.1. Chapter Overview 10.2. Partnership Models 10.3. Exosome Therapeutics: List of Partnerships and Collaborations 10.3.1. Analysis by Year of Partnership 10.3.2. Analysis by Type of Partnership 10.3.3. Analysis by Year and Type of Partnership 10.3.4. Analysis by Company and Type of Partnership 10.3.5. Analysis by Type of Technology Platform 10.3.6. Analysis by Type of Partner 10.3.7. Most Active Players: Analysis by Number of Partnerships 10.3.8. Word Cloud Analysis: Emerging Focus Areas 10.3.9. Analysis by Target Disease Indication(s) 10.3.10.Analysis by Therapeutic Area 10.3.11.Analysis by Therapeutic Area and Type of Partnership 10.3.12. Regional Distribution of Partnerships 10.3.13. Distribution by Geography 11. FUNDING AND INVESTMENT ANALYSIS 11.1. Analysis Methodology and Key Parameters 11.2. Type of Funding 11.3. Exosome Therapeutics: List of Funding Instances 11.4. Analysis by Year of Funding 11.5. Analysis by Amount Invested 11.6. Analysis by Type of Funding 11.7. Analysis by Type of Funding and Amount Invested 11.8. Analysis by Purpose of Funding 11.9. Analysis by Target Disease Indication(s) 11.10. Analysis by Therapeutic Area 11.11. Most Active Players: Analysis by Number of Funding Instances 11.12. Most Active Players: Analysis by Amount Raised 11.13. Active Investors: Analysis by Number of Funding Instances 11.14. Distribution by Geography 11.15. Summary of Funding Activity 12. START-UP HEALTH INDEXING 12.1. Analysis Methodology and Key Parameters 12.2. Analysis by Pipeline Strength 12.3. Analysis by Pipeline Maturity 12.4. Analysis by Indication Diversity 12.5. Analysis by Number of Partnerships 12.6. Analysis by Financial Support 12.7. Start-up Health Indexing: Roots Analysis Perspective 12.8. Most Active Start-ups 13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS 13.1. Chapter Overview 13.2. Exosome Development and Manufacturing Service Providers Landscape 13.2.1. Analysis by Year of Establishment 13.2.2. Analysis by Company Size 13.2.3. Analysis by Location of Headquarters 13.2.4. Analysis by Location of Headquarters and Company Size 13.3. Analysis by Type of Service(s) Offered 13.3.1. Analysis by Method of Isolation 13.3.2. Analysis by Method of Purification 13.3.3. Analysis by Method of Characterization 13.3.4. Analysis by Method of Exosome Manufacturing 13.3.5. Analysis by Scale of Operation 13.3.6. Analysis by Scalability 14. DRUG FAILURE ANALYSIS 14.1. Methodology and Key Parameters 14.2. Exosome Therapeutics: List of Failed Drug Candidates 14.2.1. Analysis by Trial Start and Discontinuation Year 14.2.2. Analysis by Trial Status of Discontinuation 14.2.3. Analysis by Target Disease Indication(s) 14.2.4. Analysis by Route of Administration 14.2.5. Analysis by Type of Sponsor 14.2.6. Analysis by Reasons for Drug Failure 14.2.7. Word Cloud Analysis: Emerging Focus Area 15. MARKET SIZING AND OPPORTUNITY ANALYSIS 15.1. Forecast Methodology and Key Assumptions 15.2. Global Exosome Therapeutics Market, 2029-2040 15.2.1. Exosome Therapeutics Market for Allogeneic Therapy, 2029-2040 (USD Million) 15.2.2. Exosome Therapeutics Market for Autologous Therapy, 2029-2040 (USD Million) 15.2.3. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2031-2040 (USD Million) 15.2.4. Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million) 15.2.5. Exosome Therapeutics Market for Fistula Perianal, 2029-2040 (USD Million) 15.2.6. Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040 (USD Million) 15.2.7. Exosome Therapeutics Market for Dermatological Disorders, 2030-2040 (USD Million) 15.2.8. Exosome Therapeutics Market for Muscoskeletal Disorders, 2031-2040 (USD Million) 15.2.9. Exosome Therapeutics Market for Ophthalmic Disorders, 2029-2040 (USD Million) 15.2.10. Exosome Therapeutics Market for Rectal Disorders, 2029-2040 (USD Million) 15.2.11. Fistula Tract Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.12. Intra-articular Exosome Therapeutics Market, 2031-2040 (USD Million) 15.2.13. Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.14. Exosome Therapeutics Market Geographical Distribution, 2029-2040 (USD Million) 15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million) 15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million) 15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million) 16. EXECUTIVE INSIGHTS 16.1. Capricor Therapeutics 16.1.1. Company Snapshot 16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer 16.2. Exogenus Therapeutics 16.2.1. Company Snapshot 16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager 16.3. ILIAS Biologics 16.3.1. Company Snapshot 16.3.2. Interview Transcript: Soonho Song, Chief Business Officer 17. APPENDIX 1: TABULATED DATA 18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html You may also be interested in the following titles: Lab Automation Market Cannabis Testing Market You may also like to learn what our experts are sharing in Roots educational series: Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic? Exploring How Artificial Intelligence Is Transforming Digital Pathology About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #ExosomeTherapeuticsMarketTrends #ExosomeTherapeuticsMarketGrowth #exosometherapies #MSCderivedexosomes #Extracellularvesicles

Cytotoxic Drugs and HPAPI Manufacturing market Professional Survey Report by 2035 The latest research report titled ‘Cytotoxic Drugs and HPAPI Manufacturing Market’, published by Roots Analysis systematically explains every single component of the Cytotoxic Drugs and HPAPI Manufacturing Market, assisting the readers with an in-depth analysis of this industry vertical. Besides, the report offers a brief overview of the different market segments and explicates the current market scenario with the help of a precise summary of the global market. The Cytotoxic Drugs and HPAPI Manufacturing Market can be characterized by its current position, industry size, anticipated revenue, and the potential market share and volume over the forecast timeframe. Alongside the above-mentioned information, the report offers meaningful insights into the regional outlook of the global market. An all-inclusive study of the competitive backdrop of the Cytotoxic Drugs and HPAPI Manufacturing Market is a significant element of the latest report. Major Highlights of the ToC: Market Dynamics: • Market Trends • Opportunities • Market Drivers • Challenges • Influence Factors Developmental Trend Analysis: • Market Trend Analysis • Market Size (Volume and Value) Methodology/Research Approach: • Research Programs/Design • Market Size Estimation • Market Breakdown and Data Triangulation • Data Source Request a sample copy of the Cytotoxic Drugs and HPAPI Manufacturing Market report https://www.rootsanalysis.com/reports/299/request-sample.html Regional Bifurcation: • The latest report categorizes the Cytotoxic Drugs and HPAPI Manufacturing Market into various regions across the globe, based on their market dominance and revenue share. • The report briefs about the market share data of each of the regional segments, along with the potential growth drivers of these regions. • The report includes valuable insights into the import and export trends, revenue estimation, and production and consumption rates, as well as the leading players of each region. Prominent factors influencing the competitive landscape of the global market: • The report offers an extensive analysis of the competitive landscape of the Cytotoxic Drugs and HPAPI Manufacturing Market, profiling the most prominent market players. • The report includes data pertaining to the manufacturing facilities of the key industry players, along with the market shares they hold and the regions they operate in. • Furthermore, the document covers the product catalog of leading companies, product specifications and common application types, pricing models, and the gross margins set by these companies. Other significant aspects determining the global market remuneration over the projected timeline: • The Cytotoxic Drugs and HPAPI Manufacturing Market report elaborates on the diverse product range, as well as the scope of product application of this particular business vertical. • The report also encompasses other vital information associated with the global market, for instance, market share, production growth rate, net profit, and application segments. • The key factors like market concentration rate, raw material processing rate, current price trends, and estimated growth prospects of the industry have also been evaluated in this report. • The report draws a precise inference of the Cytotoxic Drugs and HPAPI Manufacturing Market, giving details about the marketing approach of the leading companies, their market positions, and marketing channel development. • Additionally, the report encapsulates information related to the producers, distributors, and downstream buyers involved in this industry, and briefs about the manufacturing cost structure. Get more details on the Cytotoxic Drugs and HPAPI Manufacturing Market report https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html You may also be interested in the following titles: DNA Encoded Libraries Quantum Computing in Drug Discovery Services Market You may also like to learn what our experts are sharing in Roots educational series: Demand for Outsourcing Biologics Fill Finish Services The Future of Dentistry: Dental 3D Printing About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #CytotoxicDrugsandHPAPIManufacturingmarket #CytotoxicDrugsandHPAPIManufacturingmarketGrowth #CytotoxicDrugs #HPAPIManufacturing #hpapis